We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGN
151
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
$3K ﹤0.01%
1,826,399
– –
AORT icon
152
Artivion
AORT
$1.24B
$2K ﹤0.01%
123
– –
GNMX
153
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2K ﹤0.01%
940
-292,520
-100% -$1.32M
APVO icon
154
Aptevo Therapeutics
APVO
$3.1M
– –
0
– –
ATRC icon
155
AtriCure
ATRC
$2.86B
$1K ﹤0.01%
55
-94,345
-100% -$1.65M
XIV
156
DELISTED
VelocityShares Daily Inverse VIX Short Term ETN
XIV
$1K ﹤0.01%
+16
New +$1.02K
ACAD icon
157
CALL
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-100,000
Closed -$7K
ACHC icon
158
Acadia Healthcare
ACHC
$2.55B
$0 ﹤0.01%
+1
New +$41
AMN icon
159
AMN Healthcare
AMN
$1.32B
– –
-12,585
Closed -$484K
BCLI
160
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-26,667
Closed -$1.02M
BCRX icon
161
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-1,330,240
Closed -$8.42M
BIIB icon
162
Biogen
BIIB
$31.9B
– –
-1,922
Closed -$545K
BRKR icon
163
Bruker
BRKR
$8.49B
– –
-3
Closed –
BSX icon
164
Boston Scientific
BSX
$63.6B
$0 ﹤0.01%
3
– –
CCRN
165
DELISTED
Cross Country Healthcare
CCRN
– –
-34,819
Closed -$544K
COLL icon
166
Collegium Pharmaceutical
COLL
$711M
– –
-196,728
Closed -$3.06M
DHR icon
167
Danaher
DHR
$147B
$0 ﹤0.01%
3
– –
DIA icon
168
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45.4B
– –
-3
Closed -$1K
DVA icon
169
DaVita
DVA
$12.2B
– –
-3
Closed –
DVAX
170
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-15,600
Closed -$5K
EXAS
171
PUT
DELISTED
Exact Sciences
EXAS
– –
-200,000
Closed -$670K
GKOS icon
172
Glaukos
GKOS
$10.1B
– –
-300
Closed -$10K
GLD icon
173
SPDR Gold Trust
GLD
$145B
– –
-1
Closed –
HUM icon
174
CALL
Humana
HUM
$47.6B
– –
-40,000
Closed -$528K
ICLR icon
175
Icon
ICLR
$13.3B
– –
-6,873
Closed -$517K
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.